Innovent (01801.HK) rises 11% on Pfizer $PFE pact worth up to $10.5B
Original: Innovent Biologics shares rise 10% after pact with Pfizer of up to $10.5 billion View original →
11% was the Hong Kong move in Innovent Biologics (01801.HK) after Pfizer $PFE agreed to a global oncology collaboration worth up to $10.5B. The transaction clears the $500M Tier-1 threshold and includes 12 early-stage and de novo cancer medicines.
Pfizer's press release puts the upfront payment at $650M and potential development, regulatory, and commercial milestones at up to $9.85B. MarketScreener reported that Innovent shares rallied 11% in Hong Kong, on pace for the company's largest one-day gain in a year.
| Deal item | Figure |
|---|---|
| Total potential value | Up to $10.5B |
| Upfront payment | $650M |
| Potential milestones | Up to $9.85B |
| Programs | 12 cancer medicines |
The market stake is the valuation of China-origin oncology pipelines in global pharma portfolios. The collaboration covers antibody-drug conjugates and multi-specific antibodies, giving Pfizer access to early assets while Innovent receives non-dilutive capital and global development reach. The next checkpoints are regulatory clearance, program selection, and the first clinical milestone disclosures.
Not investment advice. Verify all figures with primary sources before acting.
Related Articles
EasyJet shares rose 10.5% after the airline agreed in principle to a £5.5B ($7.3B) takeover bid from Castlelake. The offer followed a rejected £4.93B proposal and pushed the stock to a new 52-week high.
Apollo proposed £7.15 per easyJet share, valuing the airline at about £5.7B and topping Castlelake’s £6.90 proposal. EasyJet shares rose about 14% as the board said it was minded to recommend the higher offer.
GSK $GSK agreed to acquire Nuvalent $NUVL for $10.6B in cash, offering $124 a share and a 40% premium to Nuvalent’s prior close. The transaction gives GSK two late-stage lung-cancer assets under U.S. FDA review for 2026 approvals.